Suppr超能文献

手术治疗踝关节骨折后早期与延迟负重(WAX):一项非劣效性、多中心、随机对照试验。

Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial.

机构信息

Bone and Joint Health, Blizard Institute, Queen Mary University of London, London, UK; Department of Trauma and Orthopaedic Surgery, Royal London Hospital, Barts Health NHS Trust, London, UK.

Oxford Trauma and Emergency Care, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Kadoorie Centre, University of Oxford, Oxford, UK.

出版信息

Lancet. 2024 Jun 29;403(10446):2787-2797. doi: 10.1016/S0140-6736(24)00710-4. Epub 2024 Jun 4.

Abstract

BACKGROUND

After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy.

METHODS

This was a pragmatic, multicentre, randomised, non-inferiority trial including 561 participants (aged ≥18 years) who received acute surgery for an unstable ankle fracture in 23 UK National Health Service (NHS) hospitals who were assigned to either a delayed weight-bearing (n=280) or an early weight-bearing rehabilitation strategy (n=281). Patients treated with a hindfoot nail, those who did not have protective ankle sensation (eg, peripheral neuropathy), did not have the capacity to consent, or did not have the ability to adhere to trial procedures were excluded. Neither participants nor clinicians were masked to the treatment. The primary outcome was ankle function measured using the Olerud and Molander Ankle Score (OMAS) at 4 months after randomisation, in the per-protocol population. The pre-specified non-inferiority OMAS margin was -6 points and superiority testing was included in the intention-to-treat population in the event of non-inferiority. The trial was prospectively registered with ISRCTN Registry, ISRCTN12883981, and the trial is closed to new participants.

FINDINGS

Primary outcome data were collected from 480 (86%) of 561 participants. Recruitment was conducted between Jan 13, 2020, and Oct 29, 2021. At 4 months after randomisation, the mean OMAS score was 65·9 in the early weight-bearing and 61·2 in the delayed weight-bearing group and adjusted mean difference was 4·47 (95% CI 0·58 to 8·37, p=0·024; superiority testing adjusted difference 4·42, 95% CI 0·53 to 8·32, p=0·026) in favour of early weight-bearing. 46 (16%) participants in the early weight-bearing group and 39 (14%) in the delayed weight-bearing group had one or more complications (adjusted odds ratio 1·18, 95% CI 0·80 to 1·75, p=0·40). The mean costs from the perspective of the NHS and personal social services in the early and delayed weight-bearing groups were £725 and £785, respectively (mean difference -£60 [95% CI -342 to 232]). The probability that early weight-bearing is cost-effective exceeded 80%.

INTERPRETATION

An early weight-bearing strategy was found to be clinically non-inferior and highly likely to be cost-effective compared with the current standard of care (delayed weight-bearing).

FUNDING

National Institute for Health and Care Research (NIHR), NIHR Barts Biomedical Research Centre, and NIHR Applied Research Collaboration Oxford and Thames Valley.

摘要

背景

踝关节骨折手术后,患者通常被指示避免行走 6 周(延迟负重)。术后 2 周(早期负重)开始行走可能是一种安全且更可取的康复策略。本研究旨在确定早期负重策略与延迟负重策略相比的临床和成本效益。

方法

这是一项实用的、多中心、随机、非劣效性试验,纳入了 561 名(年龄≥18 岁)在英国 23 家国民保健服务(NHS)医院接受急性不稳定踝关节骨折手术的患者,他们被分配到延迟负重(n=280)或早期负重康复策略(n=281)。接受跟骨钉治疗的患者、无保护性踝关节感觉(例如周围神经病)、无能力同意或无法遵守试验程序的患者被排除在外。参与者和临床医生均未对治疗进行掩饰。主要结局是在随机分组后 4 个月时使用 Olerud 和 Molander 踝关节评分(OMAS)测量的踝关节功能,在方案人群中进行评估。预先指定的非劣效性 OMAS 差值为-6 分,如果非劣效性成立,则在意向治疗人群中进行了优效性检验。该试验在 ISRCTN 注册处、ISRCTN12883981 进行了前瞻性注册,且该试验对新参与者关闭。

结果

在 561 名参与者中,有 480 名(86%)收集了主要结局数据。招募工作于 2020 年 1 月 13 日至 2021 年 10 月 29 日进行。在随机分组后 4 个月时,早期负重组的 OMAS 评分平均为 65.9,延迟负重组为 61.2,调整后的平均差异为 4.47(95%CI 0.58 至 8.37,p=0.024;优效性检验调整后的差异为 4.42,95%CI 0.53 至 8.32,p=0.026),表明早期负重组更有利。早期负重组有 46 名(16%)和延迟负重组有 39 名(14%)参与者发生了 1 种或多种并发症(调整后的优势比为 1.18,95%CI 0.80 至 1.75,p=0.40)。从国民保健服务和个人社会服务的角度来看,早期和延迟负重组的平均成本分别为 725 英镑和 785 英镑(平均差值为-£60 [95%CI -342 至 232])。早期负重具有成本效益的概率超过 80%。

结论

与当前的标准护理(延迟负重)相比,早期负重策略在临床上非劣效且极有可能具有成本效益。

资金

英国国民保健署(NHS)、NHS 巴茨生物医学研究中心和 NHS 应用研究合作牛津和泰晤士河谷。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验